This medication is applied across domains where additional symptomatic support may be needed in the management of distressing functional gastrointestinal disorders. It is used for the symptomatic treatment of Irritable Bowel Syndrome (IBS) and other related conditions. This makes it relevant in contexts involving acute or unstable symptom patterns arising from the bowel.

Management of Visceral Pain and Spasms

The therapeutic benefit generally supports the management of symptoms of increased neurological or muscular activity, such as symptoms related to physical discomfort and cramping. This medication is commonly used to help with these symptoms when they interfere with daily functioning or escalate during flare-ups. It may assist with easing the intensity and frequency of painful cramps, which contributes to improved comfort during periods of heightened symptoms.

Relief of Abdominal Discomfort Complex

The therapy is also relevant for easing the symptom clusters that accompany conditions involving functional stability being affected, including the persistent, uncomfortable abdominal distension, general discomfort, and flatulence. Used in scenarios where the patient experiences heightened distress, it provides supportive relief when symptoms interfere with routine activities, and may assist with maintaining functional stability during symptomatic periods.

Quick Fact: Symptomatic Support
Used for managing: Episodic or chronic abdominal pain and cramps linked to functional motility disturbances.
Patient-Oriented Benefit: Provides support that helps ease the overall symptom burden during periods of heightened symptoms.

Eligibility Profile: Who Can Use

This medicine is approved for use by adults (18 years and older), including the elderly, as the standard labeled population. Regulatory authorities have determined that patients with hepatic (liver) or renal (kidney) impairment do not require a specific dosage adjustment and are therefore eligible for use.

---

Non-Eligibility: Who Must Not Use

Use is strictly contraindicated if a patient has a known hypersensitivity or allergy to mebeverine hydrochloride or any excipient in the capsule. It is also contraindicated in individuals with specific rare hereditary sugar intolerances (such as fructose intolerance or glucose-galactose malabsorption) due to the composition of the modified-release formulation.

---

Restricted and Not Recommended Use

The medicine is not recommended for use in children and adolescents below 18 years because official labeling states that sufficient data on safety and efficacy for this formulation has not been established by regulators. Furthermore, use is not recommended during pregnancy or while breastfeeding due to a lack of adequate human safety information.

Interactions with other medicines and products

Official regulatory information for Mebeverine Hydrochloride (Мебеспалин ретард) consistently documents a minimal risk for drug–drug interactions.

Documented Interaction Profile

The limited interaction profile is attributed to the active substance's metabolism primarily through esterases (hydrolysis) rather than by the cytochrome P450 (CYP) enzyme system. This metabolic pathway is responsible for the documented lack of clinically significant metabolic interactions.

Interaction Category	Official Regulatory Statement
Interacting Medicines	None known. Regulatory documents state that no interactions with other medicines are known and no formal contraindicated combinations are listed.
Metabolic Basis	Metabolism by esterases minimizes risk of CYP-mediated pharmacokinetic interactions.
Ethanol (Alcohol)	Specific studies have confirmed the absence of any interaction between mebeverine hydrochloride and ethanol.
Timing Requirements	None. Regulatory labeling does not impose mandatory separation of administration from other medicinal products.
Specific Populations	No specific interaction risk was identified in elderly or in patients with renal and/or hepatic impairment, based on available post-marketing data.

Official Regulatory Summary

The structure of the medicine’s official interaction profile is defined by two key statements: “No interaction studies have been performed, except with alcohol,” and “No interactions with other medicines are known.” Consequently, government labeling does not require specific restrictions on co-administration with other therapeutic agents.

How Мебеспалин ретард Works: Mechanism of Action

Мебеспалин ретард (Mebeverine) functions as a myotropic antispasmodic with selective action confined primarily to the smooth muscle of the gastrointestinal (GI) tract. Its core mechanism involves the modulation of voltage-dependent ion channels —specifically potassium (K^+) channels and potentially calcium (Ca^2+) channels—on the muscle cell membrane. This modulation reduces the electrical excitability of the muscle fiber, which prevents the sustained, uncoordinated hyper-contractions characteristic of spasms.

This direct action on the muscle is supplemented by a minor, localized inhibition of norepinephrine reuptake within the enteric nervous system, contributing to the dampening of excitatory signals. This peripheral, non-anticholinergic mechanism selectively reduces muscle hyper-contractility while maintaining the organized rhythmic movement (peristalsis) necessary for efficient transit. The resulting physiological change is the reduction of heightened muscle tension and the normalization of motility patterns within the colon.

How to Use Мебеспалин ретард

This section describes the administration of Mebeverine Hydrochloride 200 mg modified-release capsules. Adherence to these methods is necessary to maintain the intended function of the modified-release formulation.

Administration Protocol

The route of administration is oral. The standard adult dosing regimen is one 200 mg modified-release capsule twice daily, typically taken once in the morning and once in the evening. This frequency is utilized due to the capsule's 'retard' (slow-release) design.

The capsule is ingested approximately 20 minutes before a meal. When taking the capsule, it must be swallowed whole with a sufficient amount of water (at least 100 mL). The capsule must not be chewed or crushed, as damaging the coating compromises the controlled release of the active substance.

Population-Specific Guidance and Course Duration

No dosage adjustment is required for older adults, or for patients with hepatic (liver) or renal (kidney) impairment.

In the event of a missed dose, the forgotten dose is skipped and the next regularly scheduled dose is taken; a double dose must not be taken to compensate. While the duration of use is not explicitly limited, the medicine is often used for the symptomatic management of flare-ups, and discontinuation may be considered when the desired effect is achieved.

Research evidence / Overview of Studies for Мебеспалин ретард

Evidence for use in Irritable Bowel Syndrome (IBS) and Related Spasms

The clinical evaluation of Mebeverine Hydrochloride, the active ingredient in Мебеспалин ретард, has primarily focused on its use in Irritable Bowel Syndrome (IBS). The research base includes numerous Randomized Controlled Trials (RCTs), where the medicine was studied against a placebo, and subsequent Systematic Reviews and Meta-Analyses which aggregate data from these trials.

In these studies, researchers examined outcomes related to physical discomfort, with a central focus on measuring changes in abdominal pain intensity and frequency. Other patient-reported outcomes describing perceived discomfort were also monitored, including global improvement in overall IBS symptoms. Findings describe patterns observed in the studies regarding how patient-reported symptoms evolved in the observed populations. Some studies reported measurements related to the primary endpoints, such as outcomes related to physical discomfort, while data show patterns related to high-level, global improvement in symptoms that varied across different systematic reviews.

Studies in Specific Patient Groups

Research has explored the use of Mebeverine in populations beyond the typical adult IBS cohort. While the majority of clinical evidence is derived from adults with various IBS subtypes, some controlled trials have also evaluated the agent in children and adolescents.

These specific studies were applied in studies examining patient-reported experiences in younger patient groups diagnosed with IBS or similar functional abdominal pain conditions. The data show patterns related to patient-reported outcomes describing perceived discomfort in these populations, but evidence is limited compared to the extensive adult data.

Duration of Studies and Long-Term Observation

Studies conducted during periods of increased symptom activity for IBS are generally designed as short-term to intermediate observations. The core clinical trials typically monitored patient responses over defined time intervals lasting from 4 weeks up to 12 weeks. This focus on short duration means that research provides context but not individual predictions.

Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes related to maintaining symptomatic changes over periods significantly longer than one year. Understanding the durability of reported patterns of relief requires further study.

Key Studies & References Irritable bowel syndrome in adults: diagnosis and management (National Institute for Health and Care Excellence - NICE Guideline CG61)

Common questions about Мебеспалин ретард (FAQ)

---

Q: Is Мебеспалин ретард a medicine intended for short-term use?

A: Regulatory documents state that the duration of use for Mebeverine is not officially limited. It is used for the symptomatic relief of flare-ups associated with IBS. Discontinuation of the medicine is generally considered when the desired symptomatic effect is achieved.

Q: What is the difference between Мебеспалин ретард and other antispasmodics mentioned in official sources?

A: Official documents classify this medicine as a musculotropic antispasmodic. This means its action is focused directly on the muscle tissue of the gut wall. This mechanism is noted in product information to avoid the systemic side effects typically associated with anti-cholinergic antispasmodics.

Q: What are the most commonly reported side effects of Мебеспалин ретард?

A: The official Summary of Product Characteristics (SmPC) lists adverse reactions, primarily related to hypersensitivity (allergic) reactions and skin conditions. However, the frequency of these events is officially classified as Not known, meaning regulatory authorities cannot reliably estimate which side effects are the most common from the available post-marketing data.

Q: Can people with lactose intolerance use the capsules of Мебеспалин ретард?

A: The medicine is contraindicated (should not be used) for individuals with specific rare hereditary sugar intolerances, such as galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. The official documentation specifically addresses these conditions.

Q: Does Мебеспалин ретард affect the absorption of other medications?

A: Regulatory information indicates the medicine is metabolized by enzymes called esterases, which reduces the risk of metabolic interactions with other medications processed by the CYP enzyme system. The official product label does not contain specific statements regarding potential effects on the absorption of other medications taken simultaneously.

Q: Is Мебеспалин ретард a treatment for the underlying cause of IBS?

A: Official documentation describes the medicine as a musculotropic antispasmodic used for the symptomatic treatment of irritable bowel syndrome. Its primary action is to relax the intestinal muscles and reduce spasms, thereby providing relief from discomfort and pain. It is used for managing the symptoms, not for treating the root cause of the condition.

Q: Can Мебеспалин ретард help with symptoms like excessive gas or bloating?

A: According to official regulatory labeling, the medicine is indicated for treating a range of IBS symptoms, which includes flatulence (excessive wind or gas). It functions to provide relief from the discomfort caused by spasms related to these symptoms.

Q: How soon after starting Мебеспалин ретард might a person notice its effect?

A: Patient information guidance indicates that the medicine generally begins to take effect about one hour after a dose is taken. This reflects the expected onset of action related to its role in relieving acute spasms and discomfort.

Q: Is dizziness or lightheadedness a known side effect of Мебеспалин ретард?

A: Post-marketing safety reports have indicated that effects such as dizziness or light-headedness can occur in some individuals. However, the frequency of these effects is not defined in the core regulatory summary.

Q: Does Мебеспалин ретард cause any known changes to bowel habits (e.g., constipation)?

A: Post-marketing safety reports, which aggregate information from real-world use, have included changes to bowel habits as possible adverse effects. These include instances of both constipation and diarrhoea in some individuals.

Q: Is it necessary to avoid specific foods or beverages when taking Мебеспалин ретард?

A: Official regulatory guidance confirms that individuals can generally eat and drink normally while using Mebeverine. The official product label does not require the avoidance of specific foods or beverages during the course of treatment.

Q: Is there any official information on using this medicine if a person has certain heart conditions?

A: Regulatory text advises that the medicine requires caution when considered for use in patients with pre-existing cardiac disorders. Specifically, regulatory information advises caution for individuals with conditions such as heart block.

Q: Is this medicine available only with a prescription?

A: The active substance, Mebeverine, is available on prescription. However, official regulatory channels permit some formulations (typically tablets, not the specific retard capsules) to be purchased without a prescription directly from a pharmacist, provided the condition has been officially diagnosed.

Q: Is Mebeverine, the active ingredient, approved for use in many countries globally?

A: Mebeverine, the active ingredient in Мебеспалин ретард, is a widely available drug that has received regulatory approval in numerous countries around the world, particularly across Europe.

Q: What are the general expectations about driving or operating machinery while using Мебеспалин ретард?

A: Official product information states that this medicine has no or negligible influence on a person's ability to safely drive vehicles or operate heavy machinery.

Q: What are the official guidelines regarding how to deal with an accidental excessive dose of Мебеспалин ретард?

A: Regulatory guidelines confirm that no specific antidote is known for an excessive dose. In such instances, symptomatic treatment (treating the symptoms that occur) is the course of action noted in official documentation. Symptoms observed in past cases were generally described as mild and rapidly reversible.

Q: Is Мебеспалин ретард related to or similar to medications that contain only digestive enzymes?

A: The medicine is classified as a musculotropic antispasmodic agent, meaning its function is to directly relax the smooth muscle of the gut and stop spasms. It is not related to or similar to medications that function as digestive enzymes, which aid in the chemical breakdown of food.

Storage and Disposal of Мебеспалин ретард

Official regulatory labeling dictates specific conditions to maintain the stability and integrity of Мебеспалин ретард (Mebeverine Hydrochloride modified-release capsules).

Mandatory Storage Requirements

Item	Requirement
Temperature	Store below 30 C.
Handling	Do not refrigerate or freeze.
Protection	Store in the original package to protect from moisture.
Child Safety	Keep out of the sight and reach of children.
Stability	Do not use the capsules after the expiry date.

Disposal Instructions

Expired or unused capsules must be managed via official pharmaceutical waste channels. Do not dispose of this medicine via wastewater or household waste. Unused capsules must be returned to a pharmacist for appropriate disposal to ensure environmental protection.